Leveraging Orthotopic Tumor Xenograft Models to Develop iPSC-Derived Cell Therapies Against Glioblastoma Multiforme

Time: 10:00 am
day: Day Two


  • Century’s iPSC NK and T cell platforms; harnessing the power of induced pluripotent stem cells to develop novel allogeneic cell therapies against multiple cancer types, including glioblastoma multiforme (GBM)
  • Introducing GBM clinical candidate selection using patient-derived cell xenografts implanted into the brain of recipient mice
  • Evaluation of the efficacy and local & systemic toxicities of CAR-iNK cells using orthotopic GBM-derived xenografts
  • Mimicking local tumor delivery of cell therapies by administering iPSCderived NK cells into the brain tumor lesion